EP0561971A1 - Fusionspolypeptide - Google Patents
FusionspolypeptideInfo
- Publication number
- EP0561971A1 EP0561971A1 EP92901817A EP92901817A EP0561971A1 EP 0561971 A1 EP0561971 A1 EP 0561971A1 EP 92901817 A EP92901817 A EP 92901817A EP 92901817 A EP92901817 A EP 92901817A EP 0561971 A1 EP0561971 A1 EP 0561971A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ala
- seq
- leu
- tyr
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 177
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 99
- 229920001184 polypeptide Polymers 0.000 title claims description 85
- 230000004927 fusion Effects 0.000 title description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 112
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 82
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 82
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 73
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 65
- 102000034288 naturally occurring fusion proteins Human genes 0.000 claims abstract description 17
- 108091006048 naturally occurring fusion proteins Proteins 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 235000018102 proteins Nutrition 0.000 claims description 86
- 101710132601 Capsid protein Proteins 0.000 claims description 48
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 42
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 40
- 101000825768 Bos taurus Somatoliberin Proteins 0.000 claims description 38
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 32
- 101710142969 Somatoliberin Proteins 0.000 claims description 32
- 102100022831 Somatoliberin Human genes 0.000 claims description 32
- 108010051696 Growth Hormone Proteins 0.000 claims description 24
- 102000018997 Growth Hormone Human genes 0.000 claims description 24
- 239000000122 growth hormone Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 17
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 229910021645 metal ion Inorganic materials 0.000 claims description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
- 235000004279 alanine Nutrition 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- 235000014304 histidine Nutrition 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
- 239000004473 Threonine Substances 0.000 claims description 11
- 235000008521 threonine Nutrition 0.000 claims description 11
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 10
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 10
- 229960002591 hydroxyproline Drugs 0.000 claims description 10
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 7
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 7
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 4
- 102000002045 Endothelin Human genes 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- NLKUJNGEGZDXGO-XVKPBYJWSA-N Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLKUJNGEGZDXGO-XVKPBYJWSA-N 0.000 claims description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102100040918 Pro-glucagon Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 3
- 108010006025 bovine growth hormone Proteins 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims description 2
- 101000983116 Homo sapiens Pancreatic prohormone Proteins 0.000 claims description 2
- 101000585528 Homo sapiens Peptide YY Proteins 0.000 claims description 2
- 101710151321 Melanostatin Proteins 0.000 claims description 2
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 2
- 108010084214 Peptide PHI Proteins 0.000 claims description 2
- 239000000132 Peptide PHI Substances 0.000 claims description 2
- 102400000096 Substance P Human genes 0.000 claims description 2
- 101800003906 Substance P Proteins 0.000 claims description 2
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims description 2
- 102000046327 human PPY Human genes 0.000 claims description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102100024819 Prolactin Human genes 0.000 claims 1
- 102400000820 Somatostatin-14 Human genes 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 25
- 238000003776 cleavage reaction Methods 0.000 abstract description 22
- 230000007017 scission Effects 0.000 abstract description 22
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 239000004606 Fillers/Extenders Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 85
- 150000001413 amino acids Chemical class 0.000 description 84
- 229940002612 prodrug Drugs 0.000 description 59
- 239000000651 prodrug Substances 0.000 description 59
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 38
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 29
- 238000000746 purification Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- -1 tPA Proteins 0.000 description 21
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 19
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 18
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 18
- 101710203526 Integrase Proteins 0.000 description 17
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 102100034343 Integrase Human genes 0.000 description 16
- 108020004511 Recombinant DNA Proteins 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 229910052751 metal Inorganic materials 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- 235000013930 proline Nutrition 0.000 description 15
- FGBLCMLXHRPVOF-IHRRRGAJSA-N Ser-Tyr-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FGBLCMLXHRPVOF-IHRRRGAJSA-N 0.000 description 14
- 108010062796 arginyllysine Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 11
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000004400 serine Nutrition 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 108010016626 Dipeptides Proteins 0.000 description 8
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000006167 equilibration buffer Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 5
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 5
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 5
- 108010047495 alanylglycine Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 108010040030 histidinoalanine Proteins 0.000 description 5
- 230000001817 pituitary effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 4
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 4
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- MIROMRNASYKZNL-ULQDDVLXSA-N Lys-Pro-Tyr Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MIROMRNASYKZNL-ULQDDVLXSA-N 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 4
- DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 4
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 3
- 108010041407 alanylaspartic acid Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 108010079317 prolyl-tyrosine Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- XIGFLVCAVQQGNS-IHRRRGAJSA-N His-Pro-His Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XIGFLVCAVQQGNS-IHRRRGAJSA-N 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- YTWNSIDWAFSEEI-RWMBFGLXSA-N Pro-His-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)O YTWNSIDWAFSEEI-RWMBFGLXSA-N 0.000 description 2
- ZUZINZIJHJFJRN-UBHSHLNASA-N Pro-Phe-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 ZUZINZIJHJFJRN-UBHSHLNASA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 2
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001295 alanines Chemical class 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 108010085325 histidylproline Proteins 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000031787 nutrient reservoir activity Effects 0.000 description 2
- 150000003148 prolines Chemical class 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- GKWWIZOKXSWGTQ-UHFFFAOYSA-N 3-(trifluoromethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(C(F)(F)F)=CC2=C1 GKWWIZOKXSWGTQ-UHFFFAOYSA-N 0.000 description 1
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 1
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 1
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- CVPXINNKRTZBMO-CIUDSAMLSA-N Glu-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N CVPXINNKRTZBMO-CIUDSAMLSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- IXHQLZIWBCQBLQ-STQMWFEESA-N Gly-Pro-Phe Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IXHQLZIWBCQBLQ-STQMWFEESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- IPIVXQQRZXEUGW-UWJYBYFXSA-N His-Ala-His Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IPIVXQQRZXEUGW-UWJYBYFXSA-N 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- RCFDOSNHHZGBOY-ACZMJKKPSA-N Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(O)=O RCFDOSNHHZGBOY-ACZMJKKPSA-N 0.000 description 1
- XOZOSAUOGRPCES-STECZYCISA-N Ile-Pro-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XOZOSAUOGRPCES-STECZYCISA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
- MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 1
- VQILILSLEFDECU-GUBZILKMSA-N Met-Pro-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O VQILILSLEFDECU-GUBZILKMSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102400000821 Somatostatin-28 Human genes 0.000 description 1
- 101800004701 Somatostatin-28 Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- LVRFMARKDGGZMX-IZPVPAKOSA-N Thr-Tyr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 LVRFMARKDGGZMX-IZPVPAKOSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KSVMDJJCYKIXTK-IGNZVWTISA-N Tyr-Ala-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 KSVMDJJCYKIXTK-IGNZVWTISA-N 0.000 description 1
- GFZQWWDXJVGEMW-ULQDDVLXSA-N Tyr-Arg-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GFZQWWDXJVGEMW-ULQDDVLXSA-N 0.000 description 1
- MDXLPNRXCFOBTL-BZSNNMDCSA-N Tyr-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MDXLPNRXCFOBTL-BZSNNMDCSA-N 0.000 description 1
- MFEVVAXTBZELLL-GGVZMXCHSA-N Tyr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-GGVZMXCHSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- GGYTXJNZMFRSLX-DFTNLTQTSA-N somatostatin-28 Chemical compound N([C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)[C@@H](C)O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO GGYTXJNZMFRSLX-DFTNLTQTSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Definitions
- FUSION POLYPEP ⁇ DES FIELD OF THE INVENTION The present invention relates to non-naturally occurring fusion polypeptides containing N-terminal portions cleavable by dipeptidylpeptidase IV (DPP IV). BACKGROUND OF THE INVENTION
- the techniques of molecular biology, specifically recombinant DNA technology, allow for the production of relatively large quantities of desirable biologically active polypeptides.
- the genetic information encoding the polypeptides may be modified to produce relatively large quantities of modified polypeptides. Modifications made to the polypeptides are often used to improve their activity or facilitate their production and/or preparation.
- DPP IV dipeptidylpeptidase IV
- DPP IV was first reported in Hopsu-Havu, V.K. and G.G. Glenner, Histo. Chemie 3:197-201 (1966) and has been shown to be present in many mammalian tissues. DPP IV is presently commercially available from Enzyme Systems Products (Dublin, California). DPP IV recognizes specific amino acid sequences on the N-terminus of proteins.
- DPP IV will cleave a dipeptide from the N-terminus when the second amino acid from the N-terminus is proline (Pro), hydroxyproline (Hyp), alanine (Ala), serine (Ser), and threonine (Thr) and any amino acid is at the N-terminus residue position provided if proline or hydroxyproline is not the amino acid residue third from the N-terminus.
- DPP IV activity is more efficient when proline or alanine is the second amino acid from the N-terminus and is usually most efficient when that position is occupied by proline.
- the activity of DPP IV in the stepwise cleavage of "PRO" parts of precursors of naturally occurring peptides is widely reported.
- biologically active proteins can be synthesized using peptide synthesizers or in host cells using recombinant DNA technology.
- biologically active proteins are administered as drugs.
- active proteins are used as therapeutics, prophylactics or to enhance or repress traits. Since DPP IV and other proteases degrade proteins, these drugs are susceptible to .degradation.
- DPP IV and other proteases degrade proteins, these drugs are susceptible to .degradation.
- a problem of using biologically active polypeptides as drugs is that their sustained presence is diminished and they must therefore be administered more frequently.
- recombinant DNA technology may be used to provide desired polypeptides in the form of non-naturally occuring proteins which contain a linker peptide that may be used as a ligand or other target for purification means.
- a linker peptide that may be used as a ligand or other target for purification means.
- U.S. patent number 4,782,137 relates to synthesis of a non- naturally occuring peptide containing an antigenic linker peptide.
- the non-naturally occuring protein can be passed through a column containing immobilized antibodies which bind to the antigenic linker, thus isolating the non-naturally occuring protein.
- Patent 4,569,794 relates to a process of purifying non-naturally occuring proteins which contain N-terminal extensions that have an affinity for immobilized metals.
- the non-naturally occuring proteins bind to immobilized metal ions in a column.
- One problem with these methods is that the linker peptide is often undesirable and removal of the linker can be difficult.
- the present invention relates to non-naturally occurring fusion proteins which comprise a core protein portion and an N-terminal extension which is cleavable by DPP IV.
- a non-naturally occuring protein is provided wherein the extension attached to the core protein is not an N-terminal extension that occurs in nature attached to the core peptide; hence, non-naturally occurring fusion protein.
- the present invention relates to prodrugs which are DPP IV cleavable non-naturally occuring proteins wherein the core protein portion is a biologically active protein.
- the present invention relates to DPP IV cleavable non- naturally occuring proteins useful in purification methods whereby the N-terminal extension provides a feature or property which facilitates purification of the non-naturally occuring protein.
- the present invention provides non-naturally occuring proteins which have N-terminal extensions that are cleavable by DPP IV such that exposure of the non-naturally occuring protein to DPP IV results in conversion of the non-naturally occuring protein to a desirable protein.
- the non-naturally occuring protein is processed into a biologically active protein in vivo using DPP IV present in the target species.
- non-naturally occuring protein can be purified by using its specifically designed N-terminus as a ligand and then processed with DPP IV to remove the N-terminal extension and liberate a desired protein.
- the present invention allows for the production of a desired protein as a non-naturally occuring protein that is later converted to the desired protein when exposed to DPP IV.
- Prodrugs are converted to drugs over a course of time using the patients' endogenous DPP IV, thereby achieving sustained presence of the active drug in a patient and reducing the frequency of administration.
- Pure desired proteins can be isolated using the present invention by producing and purifying non-naturally occuring proteins and then processing the non-naturally occuring proteins in vitro with DPP IV to produce the desired protein.
- the present invention relates to a non-naturally occurring fusion protein comprising an extension peptide portion covalently linked at its C-terminus to the N-terminus of a core protein portion, said extension peptide portion being of the formula:
- A is optional and when present is methionine; n is 0-20;
- X is selected from the group consisting of all naturally occurring amino acid residues;
- X' is selected from the group consisting of all naturally occurring amino acid residues except proline and hydroxyproline;
- Y is selected from the group consisting of proline, hydroxyproline, alanine, serine and threonine except when n is 0 then Y is selected from the group consisting of alanine, serine and threonine.
- the present invention also relates to the use of such non-naturally occuring proteins in medicinal preparations and to a method of purifying desired proteins from a mixture containing such non-naturally occuring proteins and impurities comprising the steps of selectively contacting said non-naturally occuring protein with material which immobilizes said non- naturally occuring protein, removing said impurities, separating said non-naturally occuring proteins from said material, contacting said non-naturally occuring protein with DPP IV, and isolating said desired protein.
- the invention describes a process of isolating fusion proteins which have biologically active polypeptides at the C- terminal end and an N-terminal extension linker that is a metal ion chelating linker.
- the fusion peptide has an affinity to immobilized metal ions. Impurities can be removed by passing a mixture containing the fusion protein through a column containing immobilized metal ions. The fusion protein becomes associated with the metal ions and only the impurities are eluted. Upon changing conditions the fusion peptide is liberated from the immobilized metal ions thus resulting in purified fusion protein.
- U.S. Patent No. 4,782,137 issued November 1, 1988 to Hopp et al. discloses the synthesis of a fusion protein having a highly antigenic N-terminal portion and a desired polypeptide at the C-terminal portion.
- the fusion proteins are purified from crude supernatant by passing crude supernatent through a column containing immobilized antibodies which recognize the antigenic portion of the fusion protein.
- the immobilized antibodies keep the protein in the column while the undesired components of the supernatent are eluted.
- the column conditions can then be changed to cause the antigen- antibody complex to dissociate.
- the fusion protein is then eluted and collected.
- European patent application Publication Number 0 220 958 published May 6, 1987 relates to selective chemical removal of N-terminal residues.
- the invention relates to a process and compounds useful in the process to remove N-terminal residues from desired polypeptides.
- the desired polypeptide exists as a fusion protein having the desired polypeptide link at the N- terminal to a linker having the formula X-Pro.
- a linker having the formula X-Pro Upon exposure of the fusion protein to specific buffer conditions a diketopiperazine of the X-Pro portion of the fusion protein is formed and cleaved, thereby producing the desired polypeptide from the fusion precursor.
- the fusion proteins of EPO 220,958 ('958) is not included in the present invention because according to the present invention, when the N-terminal extension is only a dipeptide, i.e., when A is absent, n is zero and X is a naturally-occuring amino acid, Y is either alanine, serine or threonine. Thus, whenever the extension is a dipeptide, it is X-Ala, X-Ser or X-Thr.
- the '958 application teaches chemical, not enzymatic, cleavage of the dipeptide X-Pro.
- the dipeptide X- Ala, X-Ser and X-Thr are not susceptible to the type chemical cleavage taught by the '958 application that cuts the X-Pro extension from the core protein.
- Australian Patent Application Document No. AU-A-12709/88 discloses fusion proteins which contain affinity peptides useful in immobilized metal affinity chromatography (IMAC).
- the affinity peptides disclosed contained at least two neighboring histidine residues.
- the IMAC purification means disclosed requires a special synthetic chemistry for making nitrilo- triacetic acid (NTA) resins.
- Tallon, M.A., et al., Biochem. 26:7767-7774 (1987) relate to synthesis of extended analogs of the fridecapeptide ⁇ -factor from Saccharomyces cerevisiae.
- the syntiiesized analog are extended ⁇ -factors, which represent sequences of naturally occurring pro- ⁇ -factor coded fo in the MF ⁇ l structural gene.
- Promelittin is the main constituent of honeybee venom. In the amino acid sequence of the N- terminal portion of the precursor, every second residue is either proline or alanine.
- DPP IV dipeptidylpeptidase IV.
- the N-terminal region of the precursor is cleaved in a stepwise fashion producing the mature protein.
- Promelittin unlike fusion proteins according to the present invention, is a naturally-occurring protein.
- the yeast ⁇ -factor unlike fusion proteins according to the present invention, is a naturally-occurrin protein.
- Mentlein, R., FEB, Vol. 234, No. 2, pp. 251-256 reviews proline residues in the maturation and degradation of peptide hormones and neuropeptides. It is reported that in mammals, proline specific proteases such as DPP IV are not involved in the biosynthesis of regulatory peptides but may play an important role in the degradation of them. Thus, it is concluded that while in vertebrates and lower vertebrates precursor proteins rely on DPP IV to convert precursors to mature forms, the processing of regulatory proteins in mammals generally uses DPP IV as a degradation protease.
- Kubiak, T.M., et al, Drug Metabolism and Disposition, Vol. 17, No. 4, pp. 393-397 (1989) refer to the in vitro metabolic degradation of bovine growth hormone releasing factor (bGRF) analogs in bovine and porcine plasma and the correlation with plasma DPP IV activity.
- the bGRF analogs tested had an Ala residue at position 2- of the N-terminus. It is reported that the metabolic degradation of bGRF in plasma is due to the presence of DPP IV in the plasma.
- Kreil, G., TIBS 15:23-26 reviews of the stepwise cleavage of dipeptides by DPP's in the conversion of precursors to final products.
- the precursors, described by Kreil are naturally-occurring proteins.
- the fusion proteins of the present invention are non-naturally- occurring fusion proteins. Boman, et al., J. Biol. Chem. 264:5852-5860 (1989) demonstrated that a dipeptidyl peptidase isolated from cecropia pupae (with similar specificity to DPP IV) was able to remove natural N-terminal sequences of Ala-Pro-Glu-Pro from the N-terminal of synthetic copies of the natural precursors of cecropia A and B.
- the preprocecropin disclosed by Boman is a naturally- occurring protein. Dalboge, H., et al, Bio/technology, 5:161-164 (February 1987) disclose converting E. coli produced precursor of human growth hormone (hGH) to authentic hGH in vitro. The N- terminal extension of the precursor is removed by dipeptidypeptidase I.
- non-naturally occurring fusion protein As used herein, the terms “non-naturally occurring fusion protein”, “non-naturally occurring fusion polypeptide”, “fusion polypeptides” and “fusion proteins” refer interchange ⁇ ably to proteins and polypeptides which do not normally occur in nature and which comprise a core protein portion and an extension portion.
- core protein As used herein "core protein”, “core protein portion” and “polypeptide portion” refers to the portion of a fusion polypeptide which is located at the C-terminus end of the molecule and which, absent the extension portion, would be a desired polypeptide and/or a biologically active protein including naturally occuring biologically active proteins and polypeptides and analogs and mutants thereof.
- N-terminal extension refers to the first up to about 45 amino acids starting at the N-terminus and which are not part of the core protein.
- prodrugs refers to fusion proteins wherein the biologically desired portion is a biologically active protein useful as a drug.
- biologically active protein and “biologically active polypeptides” refer to interchangeable proteins and polypeptides which possess biological activity.
- verified protein and “desirable protein” refer interchangeable to proteins and polypeptides which are sought in pure form.
- extension portion refers to the portion of a fusion protein which is an N-terminal extension and which is not part of the biologically desired portion.
- DPP IV cleavable N-terminal extension portion refers to the extension portion of a fusion protein which has an amino acid sequence that can be removed by the stepwise cleavage by DPP IV.
- Xaa 29 represents C-terminally amidated Argininyl residue.
- Xaa 29 represents C-terminally amidated Argininyl residue.
- Xaa 29 represents C-terminally amidated Argininyl residue.
- Xaa 29 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 33 represents C-terminally amidated Argininyl residue.
- Xaa 39 represents C-terminally amidated Argininyl residue.
- Xaa 45 represents C-terminally amidated Argininyl residue.
- Xaa 27 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Li Seq ID No. 26 Xaa 33 represents C-terminally amidated Argininyl residue.
- Xaa 35 represents C-terminally amidated Argininyl residue.
- Xaa 37 represents C-terminally amidated Argininyl residue.
- Xaa 33 represents C-terminally amidated Argininyl residue.
- Xaa 35 represents C-terminally amidated Argininyl residue.
- Xaa 37 represents C-termi ⁇ ally amidated Argininyl residue.
- Xaa 39 represents C-terminally amidated Argininyl residue.
- Xaa 45 represents C-terminally amidated Argininyl residue.
- Xaa 43 represents C-terminally amidated Argininyl residue.
- Xaa 45 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 33 represents C-terminally amidated Argininyl residue.
- Xaa 31 represents C-terminally amidated Argininyl residue.
- Xaa 33 represents C-terminally amidated Argininyl residue.
- the present invention relates to improved proteins and polypeptides.
- biologically active polypeptides are first produced as fusion proteins which contain the two portions: a first portion which represents the core protein portion; and, a second portion which is an N-terminal extension portion that is covalently linked at its carboxy terminus to the amino terminus of the first portion.
- the N-terminal extension portion of the fusion polypeptide possesses an amino acid sequence which renders it subject to cleavage by the dipeptidylpeptidase IV (DPP IV).
- DPP IV dipeptidylpeptidase IV
- a fusion protein according to the present invention has the formula: Extension portion - Core protein portion wherem "Extension portion” represents a DPP IV cleavable N-terminal extension; " - " represents a coval.ent peptide bond; and, "core protein portion” represents any desired peptide which is liberated from the Extension portion by DPP IV processing.
- the Extension portion of a fusion protein according to the present invention has an amino acid sequence according to the formula: A-X-Y(X'-Y) n wherein A is optional, and when present is methionine; n represents the number of sequentially linked X'-Y groups, that number representing from 0 to 20 of such groups, preferably 0 to 10 groups.
- X is selected from the group consisting of any naturally occuring amino acid
- Fusion proteins in which (A) is present as methionine (Met) represent sequences useful for the production of biologically active proteins by recombinant DNA methods in E. coli.
- the Met sequence present in these precursors usually will be processed by the E. coli enzymatic system or some other means which can be performed by a person with ordinary skill in the art.
- Protein synthesis in E. coli is, under normal circumstances, initiated at the translation initiation codon AUG coding for Met. As a consequence, the newly synthesized polypeptides have a methionine residue as their N-terminal amino acid.
- coli possesses an enzymatic activity with the capacity to effectively remove N-terminal Met when the Met N-terminal residue is adjacent to an amino acid with a relatively small side chain like Gly, Ala or Ser as well as Pro.
- Highly specific removal of the N-terminal Met can be accomplished using cyanogen bromide mediated cleavage of Met.
- the N-terminal Met must be the only Met in the entire protein sequence; otherwise the cleavage will take place after each Met in the sequence.
- the second amino acid from the N-terminus must be Pro, Gly, Ala or Ser if the Met is to be removed by the E. coli enzymatic system.
- the present invention relates to: recombinant DNA molecules which comprise DNA sequences that encode the fusion polypeptides; methods of using the recombinant DNA molecules; methods of using the fusion polypeptides including methods of purifying desired polypeptides and methods of delivering drugs which comprise administering prodrugs that are converted from precursor to biologically active forms by stepwise proteolytic removal of the N-terminal extension in vivo.
- Production of fusion polypeptides can be accomplished using standard peptide synthesis or recombinant DNA techniques both well known to those having ordinary skill in the art.
- Peptide synthesis is the preferred method of making polypeptides which comprise about 50 amino acids or less. For larger molecules, production in host cells using recombinant DNA technology is preferred.
- Fusion polypeptides which contain N-terminal portions that are recognized and cleaved by DPP IV are useful and advantageous over unmodified polypeptides comprising only the core protein portion.
- the present invention describes two areas of particular utility. The first use is to provide fusion polypeptides, termed "prodrugs", which comprise biologically active polypeptides that are useful as drugs covalently linked to DPP IV cleavable N-terminal extensions. These proforms can be converted into biologically active forms upon cleavage by DPP IV in the body of a human or other animal that has been administered the prodrug.
- the present invention relates to fusion polypeptides useful as prodrugs, use of fusion polypeptides in a medicinal preparation and to a method of delivering biologically active polypeptides to a patient.
- a second use for fusion polypeptides according to the present invention is in protein purification processes in which the N-terminal extension is the component of the polypeptide which renders it effective in a purification method and which N- terminal extension is then removable by cleavage using DPP IV.
- the present invention relates to fusion polypeptides useful in purification procedures and to a method of purifying desired polypeptides. These uses serve as examples to illustrate die utility of the present invention and are not meant to limit the invention in any way.
- the core protein portion of the fusion protein is liberated from the extension portion by DPP IV activity.
- the core proteins be substrates for DPP IV cleavage. That is, it is preferred that DPP IV not be able to cleave the core protein after the extension portion has been removed.
- the prodrug can result in sustained presence of the core protein since some of the DPP IV found in vivo (e.g. in plasma, kidney tissue and liver tissue) will be used to process N-terminal extensions and, therefore, delay core protein degradation.
- extension portion of the fusion protein can act as a substrate for DPP IV and competitive inhibitor, delaying the DPP IV action on the core protein thereby temporarily protecting the core protein.
- prodrug means a fusion protein which contains a DPP IV cleavable
- N-terminal extension covalently linked to a core protein portion that is a biologically active polypeptide useful as a drug.
- Prodrugs according to the present invention can be administered as an individual proform or in combination with other compounds.
- the preferred embodiment is a well defined individual form of a prodrug. In either case, the proforms are processed by naturally occurring DPP IV normally found in the body.
- prodrugs can remain active longer than unmodified molecules. Prodrugs can exist in a non-active state until such time elapses that a sufficient portion of the extension portion is degraded and the molecule becomes active. Prodrugs, therefore, can act as a time delayed drug delivery system.
- N-terminal extensions are degraded at different rates, depending on their length and the specific residues present in their amino acid sequence.
- Combinations of different forms of prodrugs having a variety of N-terminal extensions can be provided which can provide a sustained, steady level of active drug in a patient over a course of time. Prodrugs, therefore, can act as a time delayed drug delivery system.
- position one refers to the amino acid residue position at the N-terminus.
- position two refers to the amino acid residue position which is immediately adjacent to position one and which is second from the N-terminus.
- position three refers to the amino acid residue position which is immediately adjacent to position two and which is third from the N- terminus.
- the cleavage which will remove the N-terminal dipeptide occurs between position two and position three provided amino acid three is not proline or hydroxyproline and amino acid two is one of five amino acids: proline (Pro), hydroxyproline (Hyp), alanine (Ala), serine (Ser), or threonine (Thr).
- DPP IV cleaves the N-terminal residues at a different rate depending upon which of the four amino acid residues is present at position two. In most cases, DPP IV cleaves most efficiently when position two is occupied by Pro and it is next most efficient when position two is occupied by Ala. When position one is occupied by tyrosine, phenylalanine or histidine, DPP IV works at about the same rate when position two is occupied by Pro or Ala. DPP IV is next most efficient when position two is occupied by Ser. It is least efficient when Thr occupies the second position.
- a medicament can be administered which comprises either a specific prodrug or a combination of prodrug forms.
- the prodrugs, bearing an assortment of N-terminal extensions, will each be processed at a rate which is dependent upon their amino acid sequences.
- This combination of prodrug forms can be formulated to comprise a series of prodrugs that are processed into active polypeptides across a spectrum of time.
- embodiments of the present invention include hormones, receptors, enzymes, storage proteins and blood proteins.
- Specific examples include: Vasoactive Intestinal Peptide (VIP); human 0-casomorphin; Gastric Inhibitory Peptide (GLP); Gastric Releasing Peptide (GRP); human Peptide HI; human Peptide YY; fragment 7-37 of glucagon-like peptide- 1; glucagon-like peptide-2; substance P; Neuropeptide Y; human Pancreatic Polypeptide; insulin-like growth factor-1 (IGF-1); human growth hormone (hGH); bovine growth hormone (bGH); porcine growth hormone (pGH); prolactin (PRL); human, bovine, porcine or ovine growth hormone releasing factor (GRF); interleukin-1 ?
- VIP Vasoactive Intestinal Peptide
- GLP Gastric Inhibitory Peptide
- GRP Gastric Releasing Peptide
- human Peptide HI human Peptide YY;
- Smaller fusion proteins according to the present invention can be synthesized, for example, by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, California) as described in detail in PCT/US90/02923 and 07/368,231.
- genes encoding desired polypeptides are inserted in expression vectors which are then used to transform or transfect suitable host cells. The inserted gene is then expressed in the host cell and the desired polypeptide is produced.
- an additional DNA sequence is included in the gene insert. Specifically, DNA encoding the N-terminal extension residues is operably linked to the 5' end of the gene encoding the desired polypeptide.
- oligonucleotides must be designed which encode the amino acid sequence of the desired N-terminal extension and these oligonucleotides must be operably inserted upstream of the 5' end of the gene encoding the core protein portion, generating a chimeric gene.
- the techniques to make oligonucleotides and the techniques used to producing a chimeric gene are well known to those having ordinary skill in the art.
- the present invention relates to the purification and processing of biologically active recombinant polypeptides.
- the desired biologically active recombinant polypeptides are most preferably produced in a soluble form or secreted from the host.
- the extension portion of the fusion protein can be recognized by purification means.
- the fusion protein is purified from the material present in the secretion media or extraction solution it is contained in and then processed to remove the extension portion from the core protein portion, thus producing purified desired protein.
- desired proteins most suited for processing as fusion proteins according to the present invention are those biologically active polypeptides which are not themselves substrates for DPP IV cleavage.
- a gene sequence encoding for a desired protein is isolated., synthesized or otherwise obtained and operably linked to a DNA sequence coding an extension portion.
- the hybrid gene containing the gene for a desired protein operably linked to a DNA sequence encoding an extension portion is referred to as a chimeric gene.
- the present invention relates to recombinant chimeric genes which encode fusion proteins, expression vectors containing the same, hosts transformed or transfected with these expression vectors, and process for obtaining these genes, expression vectors, and hosts transformed or transfected with said vectors.
- the present invention may be used to purify any prokaryotic or eukaroytic protein that can be expressed as the product of recombinant DNA technology in a transformed or transfected host cell.
- These recombinant protein products include hormones, receptors, enzymes, storage proteins, blood proteins, mutant proteins produced by protein engineering techniques, or synthetic proteins.
- the desired polypeptides produced may include HIV RNase H, tPA, IL-1, JX-1 receptor, CD4, human nerve growth factor, sCD4-PE40, human respiratory syncytial virus (RSV) FG chimeric glycoprotein (See U.S. Patent Application Serial No. 07/543,780, incorporated herein by reference), EGF, IGF-1, IGF-2, glucagon, corticotropin releasing factor (CRF), dynorfin, endothelin, transforming growth factor (TGF- ⁇ ), Pseudomonus endotoxin 40 (PE40), transforming growth factor-/? (TGF-j8), insulin and analogs thereof.
- HIV RNase H HIV RNase H
- tPA human nerve growth factor
- sCD4-PE40 human respiratory syncytial virus
- RSV respiratory syncytial virus
- purification means examples include IMAC and immunoaffinity.
- Other purification means which employ the use of extension peptides that can be removed using DPP IV are within the contemplated scope of the present invention.
- fusion proteins comprising a biologically active polypeptide portion and an extension portion which is a metal chelating peptide are useful in an immobilized metal affinity chromatography system.
- Immobilized Metal Ion Affinity Chromatography for fractionating proteins was first disclosed by Porath, J. et al., Nature 258:598-599 (1975). Porath disclosed derivatizing a resin with iminodiacetic acid (LDA) and chelating metal ions to the IDA-derivatized resin. Porath disclosed proteins could be immobilized in a column which contained immobilized metal ions. It involves attaching a commonly used iminodiacetic acid (IDA) to a matrix followed by chelating a metal ion to the IDA-containing resin. The proteins bind to the metal ion(s) through functional groups of amino acid residues capable of donating electrons.
- LDA iminodiacetic acid
- IDA iminodiacetic acid
- IDA iminodiacetic acid
- the proteins bind to the metal ion(s) through functional groups of amino acid residues capable of donating electrons.
- Potential electron donating amino acid residues are cysteine, histidines, and tryptophan. Proteins interact with metal ions through one or more of these amino acids with electron donating side chains. Smith et al. discloses in U.S. Patent No. 4,569,794, incorporated by reference herein, that certain amino acids residues are responsible for the binding of the protein to the immobilized metal ions. However, the bound protein can be eluted by lowering the pH or using competitive counter ligands such as imidazole if histidine side chains are involved in the binding. Histidine-containing di- or tripeptides in proteins have been used to show that IMAC is a selective purification technique. Accordingly, Smith et al.
- a fusion protein comprising a metal chelating peptide covalently liked to a desired polypeptide.
- the metal chelating peptide is an extension portion that is effectively a handle to the desired polypeptide. This handle can be used in protein purification.
- Use of IMAC technology with metal chelating peptides having alternating His residues is disclosed in U.S. Patent Application Serial No. 07/506,605, which is incorporated herein by reference.
- U.S. patent application Serial No. 07/506,605 discloses specific metal chelating peptides which provide unexpectedly superior results in the IMAC purification of a fusion protein when the metal chelating peptide comprises three to six alternating His residues.
- the extension portion is a metal chelating peptide which can be represented by the formula: A-X-Y(X'-Y) n and further, wherein A is optional, and when present is me ⁇ onine; n represents the number of sequentially linked X'-Y groups, that number representing from 0 to 20 of such groups, preferably 0 to 10 groups.
- X is selected from the group consisting of any naturally occuring amino acid;
- X' is selected from the group consisting of any naturally occuring amino acid except proline or hydroxyproline; wherein at least two to three residues designated X' and, optionally, X are Histidine
- Y is Pro and n is at least 3.
- the N-terminal extension is cleaved in a stepwise fashion, producing the biologically active polypeptide provided the biologically active polypeptide is not itself a DPP IV substrate.
- Anomer example of a fusion protein includes an Extension portion having the formula
- n 3 to 8
- X is any naturally occurring amino acid
- Ys are Pro, Hyp
- N-terminal Met is a consequence of protein synthesis in E.coli and it is known to be processed by the E. coli enzymatic system when the adjacent amino acid is Pro, Gly, Ala or Ser
- the following extensions represent sequences useful for the IMAC purification and cleavage of biologically active peptides or proteins expressed intracellularly in E. coli by recombinant DNA techniques.
- the vectors could be designed so as to secrete the protein or polypeptide using an extension portion which facilitate transport, such as:
- X could be any naturally occurring amino acid compatible with the secretion system from a given host and Ys are Pro, Hyp, Ala, Ser, or Thr.
- Another protein purification system which uses fusion proteins and which is well suited for DPP IV processing technology is immunoaffinity purification.
- the fusion proteins are purified from crude supernatent by passing crude supernatent through a column containing immobilized antibodies which recognize the antigenic portion of the fusion protein.
- the immobilized antibodies keep the protein in the column while the undesired components of the supernatant are eluted.
- the column conditions can then be changed to cause the antigen- antibody complex to dissociate.
- the highly antigenic N-terminal portion of the fusion protein is an extension portion which contains DPP IV recognizable residues. After collection as described in the Hopp patent, the fusion protein according to the present invention can be exposed to DPP IV, thereby removing the extension portion.
- One of ordinary skill in the art could practice the immunoaffinity purification system of Hopp with N-terminal extensions according to the present invention.
- Contemplated equivalents include fusion proteins which have N-terminal extensions which can be processed by at least one other means such that removal of the extension is due to a combination of means. Contemplated equivalents also include fusion polypeptides comprising chemically modified amino acid residues.
- Example 1 Synthetic Prodrugs which are Fusion Prodrugs Having Core Proteins that are DPP IV Substrates Fusion polypeptides that can be synthesized and administered as prodrugs have a DPP
- extension portion represents a DPP IV cleavable N-terminal extension
- - represents a covalent peptide bond
- core protein portion represents any desired peptide which is liberated from the extension portion by DPP IV processing.
- the core protein of the fusion protein is a potential substrate for DPP IV following removal of the extension portion.
- Synthetic prodrugs can be produced using peptide synthesis techniques well known in the art.
- the core protein portion is epidermal growth factor (EGF) and the extension portion is Gly-Pro-Phe-Ala:
- the core protein portion is glucagon and the extension portion is Ala-Pro-Phe-Ala:
- the core protein portion is [Ala 15 Leu 27 ]-bGRF (1-29)NH 2 (Seq ID 3) and the extension portion is Tyr-Ala: Leu 27 ]-bGRF (1-29)NH 2 ⁇ .
- Example 2 Synthetic Prodrugs Which are Fusion Proteins Having Core Proteins that are not DPP IV Substrates
- Fusion polypeptides that can be synthesized and administered as prodrugs have a DPP IV degradable N-terminal extension covalently linked to the N-terminal of the biologically active polypeptide.
- the formula for these prodrugs can be expressed as the formula: extension portion - core protein drug portion wherein “extension portion” represents a DPP TV cleavable N-terminal extension; " - " represents a covalent peptide bond; and, "core protein portion” represents any desired peptide which is liberated from the extension portion by DPP IV processing.
- the core protein portion is a bGRF analog, [Val 2 ,Ser 8 ' 28 ,Leu 27 ]- bGRF (l-33)OH (Seq ID 1), and the extension portion is Gly-Pro-Tyr-Ala:
- the core protein portion is corticotropin releasing factor (CRF) and the extension portion is Gly-Pro-Phe-Ala: Gly ⁇ -Pro ⁇ -Phe ⁇ -Ala ⁇ -tCRF].
- CRF corticotropin releasing factor
- the core protein portion is dynorfin and the extension portion is Phe-Pro-Phe-Ala:
- the core protein portion is somatostatin-28 and the extension portion is Gly-Pro-Phe-Pro:
- the core protein portion is endothelin and the extension portion is Ala-Pro-Phe-Ala:
- the core protein portion is a bGRF analog [IIe 2 Ser 8 ' 28 Ala 15
- Leu 27 J-bGRF (1-40)OH (Seq ID 2) and the extension portion is Phe-Ala: Ser 8 ' 28 Ala 15 Leu 27 ]-bGRF (1-40)OH ⁇ .
- the core protein portion is [Ile 2 Ala 15 Leu 27 ]-bGRF (1-29) NH 2 (Seq ID 4) and the extension portion is Tyr-Ser: Ala 15 Leu 27 ]-bGRF (1-29)NH 2 ⁇ .
- Example 3 Sustained Presence of bGRF Analog Leu 27 -bGRF (1-29)NH 2
- a bGRF analog, Leu 27 -bGRF (1-29)NH 2 can be administered as a medicament comprising the core protein shown in Seq ID 5 and a variety of N-terminally extended prodrugs.
- Seq ID 5 As the core protein portion. Extension portions for these Seq ID 5-based prodrugs are Ile-Ala, Gly-Pro-Ile-Pro, Seq ID 6, Seq ID 7, Tyr-Ala, Gly-Pro-Tyr-Ala, Seq ID 8, Seq ID 9, Seq ID 10, Seq ID 11, Seq ID 12, Seq ID 13, Tyr-Ala-Tyr-Ala and Val-Ala.
- Example 4 Sustained Presence of bGRF Analog [Th ⁇ Ala ⁇ Leu ⁇ l-bGRF (1-29)NH 2
- a bGRF analog, (1-29)NH 2 can be administered as a medicament comprising the core protein portion shown in Seq ID 14 and a variety of N-terminally extended prodrugs.
- Three versions of the prodrug were made having extension portions of Tyr-Thr, Tyr-Ser, and Tyr-Thr-Tyr-Thr, respectively.
- a strategy to purify chimeric proteins from recombinant E. coli is described based on metal chelating peptide domains containing alternate histidines, with affinity for an immobilized metal ion.
- Vectors are constructed to direct the synthesis of fusion proteins using HIV RNase H as the core protein. As shown below, these fusion proteins are designed to possess alternating histidines for purification by immobilized metal ion affinity chromatography (IMAC) and alternating prolines or alternating alanines for DPP IV cleavage to remove the metal chelating peptide (mcp).
- IMAC immobilized metal ion affinity chromatography
- mcp metal chelating peptide
- Fusion protein HIVRH/mcp #1 comprises an N-terminal extension of Seq ID 15 linked to HIV RNase H: Met ⁇ Pro- ⁇ -Ala ⁇ -His ⁇ -Pro ⁇ -His ⁇ -Pro ⁇ -His ⁇ -Pro ⁇ -His ⁇ -Pro ⁇ -His ⁇ -Ala ⁇ - ⁇ HIV
- Fusion protein HIVRH/mcp #2 comprises an N-terminal extension of Seq ID 16 linked to HIV RNase H:
- Fusion protein HIVRH/mcp #3 comprises an N-terminal extension of Seq ID 17 linked to HIV RNase H:
- a chimeric gene is inserted into the final expression vector.
- Expression vectors containing the chimeric gene constructs are used to transform E. coli by standard techniques. Expression of the genes in E. coli results in the production of the fusion proteins encoded by the chimeric genes. These fusion proteins contain HIV RNase H amino acids and an N-terminal extension which contains alternate histidines (metal chelating peptide) and alternate prolines or alanines.
- E. coli cell paste Approximately 3 g of E. coli cell paste is suspended in 30 ml of 0.25 M potassium phosphate, pH 7.2 containing 1 mM dithiothreitol (DTT), EDTA, phenylmethylsulfonyl fluoride (PMSF), and benzamidine HCL, 10 mg/liter aprotinin, leupeptin, and bestatin.
- This suspension is passed through a French Press three times to break the cells. Cell lysates are centrifuged at 12,000 rpm for 1 hr. The supernatant is removed and solid ammonium sulfate added to 70% saturation. After stirring for 1 hr, the suspension is centrifuged at 12,000 rpm for 1 hr.
- the supernatant is discarded and the pellet is redissolved in 2.25 mis of 50 mM Tris pH 7.5 containing 1 mM DTT, PMSF, and benzamidine.
- the solution is then dialyzed overnight in 20 mM Tris, 50 mM NaCl, 1 mM DTT, 10% glycerol, and 0.1 mM EDTA pH 7.5 (Buffer A) at 4°C.
- the dialysate is collected, diluted with one volume of Buffer A, and applied to a 10 ml column of washed DEAE cellulose equilibrated in Buffer A. The run through is collected batchwise and the column further washed with 50 mis of Buffer A.
- IMAC columns are prepared as follows. Chelating Sepharose Fast Flow from Pharmacia is washed thoroughly with Milli-Q water on a scintered glass filter. The gel is then resuspended in water to form a slurry. The slurry is poured carefully into a glass column (Pharmacia) to a volume of 6 mis (1 x 7 cm). After the gel has settled, the column is washed with 5 volumes of 50 mM EDTA (ethylenediaminetetraacetic acid) pH 8.0. Following this, the column is washed with 5 volumes of 0.2 N NaOH and 5 volumes of Milli-Q water. The column then is charged with 5 volumes of 50 mM NiSo (or ZnCl 2 or Q1SO4).
- EDTA ethylenediaminetetraacetic acid
- the column is washed with 5 bed volumes of equilibration buffer.
- the equilibration buffer is made up of 20 mM Tris pH 8.0, containing 500 mM NaCl, 1 mM PMSF, 1 mM benzamidine, 10 mg/L leupeptin, and 10 mg/L aprotinin.
- the column has been equilibrated with at least 5 volumes of equilibration buffer. 5-10 mis of crude recombinant E. coli extract are applied to the column by gravity. After all the crude material has entered the column, the column is washed with 10 column volumes of equilibration buffer containing 1.0 M NaCl, instead of 500 mM NaCl, pH 8.0.
- the column is then eluted with increasing concentrations of imidazole in the equilibration buffer at pH 8.0.
- a large number of elutions are performed for each experiment to determine the concentration at which the chimeric eluted. Later this elution is simplified and usually just three imidazole concentrations are used: 35 mM, 100 mM, and 300 mM imidazole in the equilibration buffer, pH 8.0.
- Ten bed volumes of each imidazole buffer are used.
- the column is washed wi 10 volumes of equilibration buffer.
- the column is stripped with 5 bed volumes of 50 mM EDTA pH 8.0 to determine if any protein is still bound to the column.
- the flow rates for the columns are l.O ml/min. 5 ml fractions are collected. The columns are run at room temperature.
- HIV RNase H activity is determined by the method described in Becerra, S. P. et al,
- DPP IV purified from human placenta (Enzyme Systems Products, Dublin, Ca.) with a specific activity of 5200 mU per mg protein is used.
- One U is equivalent to hydrolysis of 1 umole of a synthetic substrate, Ala-Pro-7-amino-4-2 trifluoromethyl coumarin in one minute at pH 7.8.
- Enzymatic conversion is carried out by incubation of the fusion protein (about 1-100 mg) at a concentration of 1-10 mg/ml with DPP IV at 25 degrees C for 30 minutes at an enzyme to substrate ratio of 1:100 (w/w).
- the desired polypeptide is recovered from the uncleaved fusion protein by IMAC. The authenticity is confirmed by N-terminal sequence analysis.
- Example 6 Processing of bGRF Analog prodrugs in bovine plasma in vitro.
- Table 1 summarizes representative experiments to demonstrate generation of the core peptide,
- Tyr _4 -Ala" 3 -Tyr- 2 -Ala' 1 - ⁇ [Leu 27 ]-bGRF(l-29)NH 2 ⁇ was sequentially converted over time to Tyr _2 -Ala "1 - ⁇ [Leu 27 ]-bGRF(l-29)NH 2 ⁇ (Seq ID 25), [Leu 27 ]-bGRF(l- 29)NH 2 ( ⁇ re peptide, Seq ID 5) and finally to [Leu 27 ]-bGRF(3-29)NH 2 (Seq. ID 24).
- Tyr- 2 -Ala- 1 - ⁇ ILeu 27 ]-bGRF(l-29)NH 2 ⁇ was converted to [Leu 27 ]-bGRF(l-
- GH plasma growth hormone
- bGRF prodrugs having DPP-IV-cleavable N-terminal extensions were processed successfully to produce the core peptide(s) in bovine plasma in vitro via DPP-IV mediated cleavages;
- the in vitro half-life of the core peptide generated from the prodrugs was significantly longer and was a function of the N-terminal extension length in the prodrug;
- the fact that the bGRF prodrugs with very low inherent potency were as effective as the core peptide in the release of GH in vivo indicates that most likely the core peptide was generated in vivo as anticipated.
- Example 8 Preparation of Gly ⁇ -Pro ⁇ -Ile ⁇ -Pro -1 ⁇ [Leu 27 ] bGRF(l-29)NH 2 ⁇ , trifluoroacetate salt.
- Example 9 Preparation of Tyr ⁇ -Ala ⁇ -Gly ⁇ -Pro ⁇ -Ile ⁇ -Pr ⁇ - 1 ⁇ [Leu 27 ] bGRF(l-29)NH 2 ⁇ , trifluoroacetate salt.
- the synthesis of the GRF analog peptide Seq ID 27 which comprises Seq ID 6 as the extension portion and which has the formula: #3H-Tyr-Ala-Gly-Pro-Ile-Pro-Tyr-Ala-Asp-Ala-IIe-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly- Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Asn-Arg-NH 2 (as the CF 3 COOH salt) is conducted in a stepwise manner as in procedure A which is described in published PCT patent application PCT/US90/02923 incorporated herein by reference
- Example 19 Preparation of Tyr ⁇ -Thr "1 ⁇ [Ala 15 Leu 27 ] bGRF(l-29)NH 2 ⁇ , trifluoroacetate salt.
- Example 23 Preparation of Tyr ⁇ -Thr ⁇ -Tyr ⁇ -Thr 1 ⁇ [Thr 2 Ala 15 Leu 27 ] bGRF(l-29)NH 2 ⁇ , trifluoroacetate salt.
- Analysis A includes all steers and Analysis B includes only steers responding to GRF injection and control steers.
- e Vajygg with different superscripts in a column are significantly different (P ⁇ .05).
- Analysis A includes all steers and Analysis B includes only steers responding to GRF injection and control steers.
- b ⁇ ⁇ v a j ues >vith different superscripts in a column are significantly different (P ⁇ .05).
- ADDRESSEE Upjohn Company - Corp. Patents & Trademarks
- B STREET: 301 Henrietta Street
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62672790A | 1990-12-13 | 1990-12-13 | |
US626727 | 1990-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0561971A1 true EP0561971A1 (de) | 1993-09-29 |
Family
ID=24511577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92901817A Withdrawn EP0561971A1 (de) | 1990-12-13 | 1991-12-12 | Fusionspolypeptide |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0561971A1 (de) |
JP (1) | JPH06503473A (de) |
AU (1) | AU662508B2 (de) |
CA (1) | CA2094512A1 (de) |
CZ (1) | CZ109393A3 (de) |
FI (1) | FI932680A (de) |
HU (1) | HUT69963A (de) |
IE (1) | IE914347A1 (de) |
NO (1) | NO932148L (de) |
RU (1) | RU2114119C1 (de) |
SK (1) | SK60893A3 (de) |
TW (1) | TW213923B (de) |
WO (1) | WO1992010576A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US6759393B1 (en) | 1999-04-12 | 2004-07-06 | Pfizer Inc. | Growth hormone and growth hormone releasing hormone compositions |
CA2303702A1 (en) * | 1999-04-12 | 2000-10-12 | Pfizer Products Inc. | Growth hormone and growth hormone releasing hormone compositions |
WO2001036643A1 (en) * | 1999-11-19 | 2001-05-25 | Transkaryotic Therapies, Inc. | Nucleic acid construct for optimized production of products |
EP1205551A1 (de) * | 2000-11-09 | 2002-05-15 | Pfizer Products Inc. | Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen |
ATE498404T1 (de) | 2003-12-09 | 2011-03-15 | Novo Nordisk As | Regulierung der nahrungspräferenz mit glp-1- agonisten |
WO2005120492A1 (en) | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1996937A4 (de) † | 2006-03-06 | 2009-04-08 | Amunix Inc | Genetische packungen und verwendungen davon |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US9447150B2 (en) | 2010-01-29 | 2016-09-20 | Iowa State University Research Foundation, Inc. | Peptide domains that bind small molecules of industrial significance |
CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
JP7046990B2 (ja) * | 2017-06-29 | 2022-04-04 | ユレカ・ソシエテ・ア・レスポンサビリテ・リミテ | 医薬的特性が改善されたプロドラッグペプチド |
SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) * | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4569794A (en) * | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
CA1340522C (en) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
EP0477217B1 (de) * | 1989-06-16 | 1994-11-09 | The Upjohn Company | Stabilisierte, starke grf-analoga |
ES2088495T3 (es) * | 1990-04-09 | 1996-08-16 | Upjohn Co | Procedimiento mejorado de purificacion de proteinas recombinantes y compuestos utiles en dicho procedimiento. |
-
1991
- 1991-12-12 SK SK60893A patent/SK60893A3/sk unknown
- 1991-12-12 EP EP92901817A patent/EP0561971A1/de not_active Withdrawn
- 1991-12-12 HU HU9301705A patent/HUT69963A/hu unknown
- 1991-12-12 AU AU91165/91A patent/AU662508B2/en not_active Ceased
- 1991-12-12 CA CA002094512A patent/CA2094512A1/en not_active Abandoned
- 1991-12-12 RU RU93045577A patent/RU2114119C1/ru active
- 1991-12-12 CZ CS931093A patent/CZ109393A3/cs unknown
- 1991-12-12 WO PCT/US1991/009152 patent/WO1992010576A1/en not_active Application Discontinuation
- 1991-12-12 JP JP4501996A patent/JPH06503473A/ja active Pending
- 1991-12-13 IE IE434791A patent/IE914347A1/en not_active Application Discontinuation
- 1991-12-17 TW TW080109839A patent/TW213923B/zh active
-
1993
- 1993-06-11 NO NO93932148A patent/NO932148L/no unknown
- 1993-06-11 FI FI932680A patent/FI932680A/fi not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9210576A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU662508B2 (en) | 1995-09-07 |
TW213923B (de) | 1993-10-01 |
NO932148D0 (no) | 1993-06-11 |
WO1992010576A1 (en) | 1992-06-25 |
HU9301705D0 (en) | 1993-10-28 |
SK60893A3 (en) | 1993-10-06 |
CA2094512A1 (en) | 1992-06-14 |
FI932680A0 (fi) | 1993-06-11 |
AU9116591A (en) | 1992-07-08 |
FI932680A (fi) | 1993-06-11 |
JPH06503473A (ja) | 1994-04-21 |
NO932148L (no) | 1993-08-09 |
HUT69963A (en) | 1995-09-28 |
IE914347A1 (en) | 1992-06-17 |
RU2114119C1 (ru) | 1998-06-27 |
CZ109393A3 (en) | 1994-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU662508B2 (en) | Fusion polypeptides | |
CA2367856C (en) | Analogs of gastric inhibitory peptide and their use for treatment of diabetes | |
EP0518587B1 (de) | A-C-B-Proinsulin, Verfahren zu seiner Herstellung und Verwendung, und Zwischenprodukte in der Insulin-Produktion | |
US7595294B2 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
AU693815B2 (en) | Enzymatic method for modification of recombinant polypeptides | |
US7566691B2 (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
JP4624495B2 (ja) | ヒト・インスリンの生成 | |
NZ338004A (en) | Process for producing peptide with glucagon like peptide-1 (GLP-1) activity by incorporating a protective and helper component to facilitate purification | |
WO2022227707A1 (zh) | 一种双靶点融合蛋白的制备方法和应用 | |
JP5331685B2 (ja) | 二塩基性b鎖末端を有するインスリン類似体の生産方法 | |
EP1179593B1 (de) | Verfahren zur herstellung von rekombinantem insulin durch fusionsproteine | |
Chunxiao et al. | Study on preparation and activity of a novel recombinant human parathyroid hormone (1–34) analog with N-terminal Pro–Pro extension | |
EP0381433A1 (de) | Methode zur Produktion von Glukagon | |
US4732972A (en) | Polypeptides having growth hormone releasing activity | |
RU2792236C9 (ru) | Производное полипептида и способ его получения | |
RU2792236C1 (ru) | Производное полипептида и способ его получения | |
HU211572A9 (hu) | Fúziós polipeptidek. Az átmeneti oltalom az 1-38. igénypontra vonatkozik | |
JPH0394682A (ja) | ペプチドの製造法 | |
JPH01215296A (ja) | ヒトセクレチン前駆体物質およびその製造法ならびにその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930709 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19960131 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHARMACIA & UPJOHN COMPANY |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19971110 |